InViragen Hand, Foot and Mouth Disease Vaccine Generates Immune Responses in 100% of Study Participants
Published: Mar 12, 2012
SINGAPORE--(BUSINESS WIRE)--Inviragen today reported top-line results of a placebo-controlled, randomized Phase 1 trial of INV21, the Company’s highly purified virus particle vaccine against Hand, Foot and Mouth Disease (HFMD) caused by enterovirus 71 (EV71). In the clinical study, healthy adults received two immunizations each of either a high- or low-dose formulation of INV21. Study participants were monitored for safety and for immune response after each administration. Antibodies that neutralize the EV71 virus were measured in individuals who received both doses of the vaccine. One hundred percent of individuals who received the vaccine had significantly increased EV71 immune responses after immunization, which may signify protection against infection. Further, INV21 was safe and well tolerated in this population. Inviragen expects to present complete safety and immunogenicity data at an appropriate infectious disease meeting in 2012.